Full Press Release Details
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting.
BIIB
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting
Key Takeaway: Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis